Evinova aims to scale and bring to market digital health tools already used by AstraZeneca to expedite the clinical trial process. Additionally, Evinova will also look to develop a portfolio of remote patient monitoring and digital therapeutics, according to a Nov. 20 AstraZeneca news release.
So far, Evinova has created a drug development suite of digital health, artificial intelligence, and machine learning tools that aim to help support the drug creation process.
“The future of medicine development can be accelerated with digital solutions,” AstraZeneca CEO Pascal Soriot said in the news release. “We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
